for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

La Jolla Pharmaceutical Company

LJPC.OQ

Latest Trade

4.02USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.31

 - 

9.37

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.02
Open
--
Volume
--
3M AVG Volume
9.87
Today's High
--
Today's Low
--
52 Week High
9.37
52 Week Low
2.31
Shares Out (MIL)
27.36
Market Cap (MIL)
111.91
Forward P/E
-2.86
Dividend (Yield %)
--

Next Event

La Jolla Pharmaceutical Co Annual Shareholders Meeting

Latest Developments

More

La Jolla Pharmaceutical Chief Commercial Officer Was Terminated Without Cause

La Jolla Pharmaceutical Company To Acquire Tetraphase Pharmaceuticals

La Jolla Pharmaceutical Reports A Stake Of 14.9% In Tetraphase Pharmaceuticals Inc As Of June 15

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is focused on development and commercialization of therapies for patients suffering from life-threatening diseases. The Company’s products include GIAPREZA, XERAVA, LJPC-0118 and LJPC-401. The GIAPREZA (angiotensin II) is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shock. The XERAVA (eravacycline) is a tetracycline class antibacterial indicated for the treatment of intra-abdominal infections in patients 18 years of age and older. The LJPC-0118 (I.V. artesunate) is the Company’s investigational product for the treatment of malaria. The LJPC-401 (synthetic human hepcidin) is the Company’s investigational product for the treatment of conditions characterized by iron overload.

Industry

Biotechnology & Drugs

Contact Info

4550 Towne Centre Ct

SAN DIEGO, CA

92121-1900

United States

+1.858.2074264

http://www.ljpc.com

Executive Leadership

Kevin C Tang

Chairman of the Board

Larry G. Edwards

President, Chief Executive Officer

Michael S. Hearne

Chief Financial Officer, principal financial officer, Principal Accounting Officer

Laura Johnson Douglass

Independent Director

Craig A. Johnson

Independent Director

Key Stats

2.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-5.410

2018

-7.850

2019

-4.300

2020(E)

-1.865
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.25
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-66.20
Return on Equity (TTM)
-56.68

Latest News

Latest News

BRIEF-La Jolla Pharmaceutical Company To Acquire Tetraphase Pharmaceuticals

* LA JOLLA PHARMACEUTICAL COMPANY TO ACQUIRE TETRAPHASE PHARMACEUTICALS, INC.

BRIEF-La Jolla Pharmaceutical Reports A Stake Of 14.9% In Tetraphase Pharmaceuticals Inc As Of June 15

* LA JOLLA PHARMACEUTICAL CO REPORTS A STAKE OF 14.9% IN TETRAPHASE PHARMACEUTICALS INC AS OF JUNE 15 - SEC FILING

BRIEF-Tetraphase Receives Proposal from La Jolla, Determination of Superior Offer, Notice to Melinta

* TETRAPHASE ANNOUNCES RECEIPT OF PROPOSAL FROM LA JOLLA PHARMACEUTICAL COMPANY, DETERMINATION OF SUPERIOR OFFER AND NOTICE TO MELINTA

BRIEF-La Jolla Says Board Approved Restructuring Plan To Align Organization With Focus On Commercialization Of Giapreza

* LA JOLLA PHARMACEUTICAL CO - ON MAY 28, BOARD APPROVED RESTRUCTURING PLAN TO ALIGN ORGANIZATION WITH SOLE FOCUS ON COMMERCIALIZATION OF GIAPREZA

BRIEF-La Jolla Says Submitted Non-Binding Offer To Acquire 100% Of Equity Of Tetraphase

* LA JOLLA PHARMACEUTICAL -ON MAY 6, SUBMITTED NON-BINDING OFFER TO ACQUIRE 100% OF EQUITY OF TETRAPHASE PHARMACEUTICALS IN AN ALL-CASH TRANSACTION Source: (https://bit.ly/3bcc4H8) Further company coverage:

BRIEF-La Jolla Pharmaceutical Reports Quarterly Loss Per Share $0.32

* COMPANY ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2020

BRIEF-La Jolla Pharmaceutical To Provide Giapreza™ For Patients With Septic Shock Due To COVID-19 In Brussels

* LA JOLLA PHARMACEUTICAL COMPANY TO PROVIDE GIAPREZA™ (ANGIOTENSIN II) FOR EMERGENCY MEDICAL PROGRAM IN PATIENTS WITH SEPTIC SHOCK DUE TO COVID-19 AT CHIREC DELTA HOSPITAL, BRUSSELS, BELGIUM Source text for Eikon: Further company coverage:

BRIEF-La Jolla To Provide Giapreza For Patients With Septic Shock From COVID-19 In Germany

* LA JOLLA PHARMACEUTICAL COMPANY TO PROVIDE GIAPREZA™ (ANGIOTENSIN II) FOR NAMED PATIENT EMERGENCY USE IN PATIENTS WITH SEPTIC SHOCK DUE TO COVID-19 AT UNIVERSITY HOSPITAL MÜNSTER IN GERMANY Source text for Eikon: Further company coverage:

BRIEF-La Jolla Says Providing Giapreza In Patients With Septic Shock Due To COVID-19

* LA JOLLA - PROVIDING GIAPREZA FOR NAMED PATIENT EMERGENCY USE IN PATIENTS WITH SEPTIC SHOCK DUE TO COVID-19 AT ROYAL SURREY COUNTY HOSPITAL Source text for Eikon: Further company coverage:

BRIEF-La Jolla Pharmaceutical To Provide Giapreza™ For Named Patient Emergency Use In Patients With Septic Shock Due To Covid-19 At University Hospital Frankfurt In Germany

* LA JOLLA PHARMACEUTICAL COMPANY TO PROVIDE GIAPREZA™ (ANGIOTENSIN II) FOR NAMED PATIENT EMERGENCY USE IN PATIENTS WITH SEPTIC SHOCK DUE TO COVID-19 AT UNIVERSITY HOSPITAL FRANKFURT IN GERMANY Source text for Eikon: Further company coverage:

BRIEF-La Jolla Pharmaceutical Company To Provide GIAPREZA For Named Patient Emergency Use In Patients With Septic Shock Due To COVID-19

* LA JOLLA PHARMACEUTICAL COMPANY TO PROVIDE GIAPREZA™ (ANGIOTENSIN II) FOR NAMED PATIENT EMERGENCY USE IN PATIENTS WITH SEPTIC SHOCK DUE TO COVID-19 AT GUY’S AND ST. THOMAS’ NHS FOUNDATION TRUST, LONDON, UNITED KINGDOM Source text for Eikon: Further company coverage:

BRIEF-La Jolla Pharmaceutical To Provide GIAPREZA In Italy For Use In Patients With Septic Shock Associated With COVID-19

* LA JOLLA PHARMACEUTICAL CO - PROVIDING GIAPREZA IN ITALY FOR COMPASSIONATE USE IN PATIENTS WITH SEPTIC SHOCK ASSOCIATED WITH COVID-19 Source text for Eikon: Further company coverage:

BRIEF-La Jolla Pharmaceutical Posts Qtrly Loss Per Share Of $0.93

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2019

BRIEF-La Jolla Pharmaceutical Co Announces $125 Mln Royalty Financing Agreement With Healthcare Royalty Partners

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES $125 MILLION ROYALTY FINANCING AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS Source text for Eikon: Further company coverage:

BRIEF-La Jolla Pharmaceutical Quarterly Loss Per Share $2.22

* LA JOLLA PHARMACEUTICAL ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2018 AND RECENT CORPORATE PROGRESS

BRIEF-La Jolla PharmaAnnounces Launch Of Giapreza In United States

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES LAUNCH OF GIAPREZA™ (ANGIOTENSIN II) IN THE UNITED STATES

BRIEF-La Jolla Pharmaceutical Announces Pricing Of Public Offering Of Common Stock

* SAYS PUBLIC OFFERING OF 3.40 MILLION COMMON SHARES PRICED AT $29.50PER SHARE

BRIEF-La Jolla Pharmaceutical Company Announces $100 Million Public Offering Of Common Stock

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES $100 MILLION PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-La Jolla Pharmaceutical Q4 Loss Per Share $1.74

* MPANY ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017 AND RECENT CORPORATE PROGRESS

BRIEF-La Jolla Pharmaceutical Announces Treatment Of First Patient In Giapreza Pediatric Study

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES THE TREATMENT OF FIRST PATIENT IN GIAPREZA (ANGIOTENSIN II) PEDIATRIC STUDY Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up